The VESPA Pilot Study
NCT04756245
Recruiting
Physical activity has been described by the US federal government as a 'best buy' for public health. Unfortunately, most adults in the United States are not sufficiently active, and this worsens with age. Low levels of participation are driven by many challenging barriers, including lack of access, few opportunities for enjoyable activity, and few supportive social relationships, which is especially important given the central role of social connection for lasting behavior change. A half-centur... Read More
Gender:
ALL
Ages:
Between 45 years and 80 years
Trial Updated:
07/14/2025
Locations: Wake Forest University, Winston-Salem, North Carolina
Conditions: Exercise, Behavior, Loneliness, Social Isolation
Register for Updates
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability
NCT04804644
Recruiting
This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer that has spread to the brain. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Whole brain radiation therapy delivers a low dose of radiat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: Mayo Clinic Hospital in Arizona, Phoenix, Arizona +213 locations
Conditions: Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Register for Updates
Senicapoc in Alzheimer's Disease
NCT04804241
Recruiting
Development of novel disease-modifying therapies for Alzheimer's disease (AD) remains of paramount importance. This study will be a Phase II randomized clinical trial testing Senicapoc in patients with mild or prodromal AD. This will be a small Proof of Mechanism study to prove biological activity and target engagement in humans with early AD. The investigators will study up to 55 patients over 52 weeks, with primary outcomes being Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Co... Read More
Gender:
ALL
Ages:
Between 55 years and 85 years
Trial Updated:
07/14/2025
Locations: University of California, Davis Alzheimer's Disease Center, Sacramento, California +1 locations
Conditions: Mild Cognitive Impairment, Alzheimer Disease
Register for Updates
Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma
NCT04865939
Recruiting
There is a high rate of intravesical (bladder) recurrence following extirpative surgery for upper tract urothelial carcinoma. There is no single established standard of care for prevention of intravesical recurrence; however, one protocol in common use involves the use of intravesical gemcitabine instilled into the bladder during surgery and prior to entry into the bladder. There are barriers to the use of gemcitabine, especially at lower volume centers. Some evidence suggests that intravesical... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
07/14/2025
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma Ureter
Register for Updates
Study of OCTAPLEX in Patients With Acute Major Bleeding on DOAC Therapy With Factor Xa Inhibitor
NCT04867837
Recruiting
This is a multicentre, prospective, randomised, double-blinded, group-sequential, parallel-group, adaptive design, phase 3 study to demonstrate the haemostatic efficacy and safety of four-factor prothrombin complex concentrate, OCTAPLEX, in patients with acute major bleeding on DOAC therapy with factor Xa inhibitor. Patients will be randomised 1:1 to either of two study groups: low-dose vs. high-dose OCTAPLEX.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: Harbor-UCLA Medical Center, Torrance, California +62 locations
Conditions: Acute Major Bleeding
Register for Updates
Repurposing Low-Dose Clonidine for PTSD in Veterans
NCT04877093
Recruiting
Hypothesis: Veterans with PTSD prescribed clonidine will demonstrate improvements in PTSD symptoms, including daytime, nighttime, and sleep-related behaviors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: Aurora Psychiatric Hospital, Wauwatosa, Wisconsin
Conditions: PTSD, Posttraumatic Stress Disorder, Sleep
Register for Updates
SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma
NCT04923126
Recruiting
This is an open-label, multi-center, Phase 1/2 study of the brain-penetrant MEK inhibitor, mirdametinib (PD-0325901), in patients with pediatric low-grade glioma (pLGG).
Gender:
ALL
Ages:
Between 2 years and 24 years
Trial Updated:
07/14/2025
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Low-Grade Glioma, Recurrent Low-Grade Glioma, Progressive Low-Grade Glioma
Register for Updates
A Study to Evaluate Breathing Muscle Training in Cardiac Rehab
NCT04984473
Recruiting
The purpose of this study is to understand if breathing muscle training combined with cardiac rehabilitation influences the blood flow and blood pressure response during exercise.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Healthy, Heart Failure
Register for Updates
BOLT: Study of the Indigo® Aspiration System When Used in Patients With Deep Vein Thrombosis
NCT05003843
Recruiting
The objective of this study is to demonstrate the safety and efficacy of the Indigo Aspiration system for percutaneous mechanical thrombectomy in a population presenting with obstruction due to deep vein thrombosis (DVT) who are eligible for treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: Sharp Grossmont, La Mesa, California +41 locations
Conditions: Deep Vein Thrombosis, DVT
Register for Updates
The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease
NCT05009862
Recruiting
The purpose of this study is to understand how the drug rivaroxaban improves symptoms associated with peripheral artery disease.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
07/14/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Peripheral Arterial Disease
Register for Updates
Reducing Pregnancy Risks: The Mastery Lifestyle Intervention
NCT05012072
Recruiting
This randomized controlled trial will test an intervention called the Mastery Lifestyle Intervention (the MLI) that was developed from data of 1000+pregnant Hispanic women related to risks of preterm birth. The investigators will deliver a psychoeducational intervention that is manualized over 6 group sessions. The investigators will also have a usual care group that receives standard prenatal care. The investigators plan to enroll 238 pregnant women and start the study with them at 14-20 weeks... Read More
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
07/14/2025
Locations: Women's Specialist of PLLC, Webster, Texas
Conditions: Mental Health Wellness 1, Preterm Birth
Register for Updates
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
NCT05050084
Recruiting
This phase III trial uses the Decipher risk score to guide therapy selection. Decipher score is based on the activity of 22 genes in prostate tumor and may predict how likely it is for recurrent prostate cancer to spread (metastasize) to other parts of the body. Decipher score in this study is used for patient selection and the two variations of treatment to be studied: intensification for higher Decipher score or de-intensification for low Decipher score. Patients with higher Decipher risk scor... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +562 locations
Conditions: Prostate Adenocarcinoma
Register for Updates